Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Bemnifosbuvir

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Atea Supports Bemnifosbuvir-Ruzasvir Combo for Hepatitis C at AASLD
    Atea Supports Bemnifosbuvir-Ruzasvir Combo for Hepatitis C at AASLD

    15 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/15/2982131/0/en/Atea-Pharmaceuticals-Presents-Multiple-New-Datasets-Supporting-the-Combination-of-Bemnifosbuvir-and-Ruzasvir-for-the-Treatment-of-Hepatitis-C-Virus-at-AASLD-s-The-Liver-Meeting-202.html

    GLOBENEWSWIRE
    15 Nov 2024
    Share Share
    Larimar Therapeutics Reports Q3 2024 Finacial Results
    Larimar Therapeutics Reports Q3 2024 Finacial Results

    30 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/30/2971559/0/en/Larimar-Therapeutics-Reports-Third-Quarter-2024-Operating-and-Financial-Results.html

    GLOBENEWSWIRE
    30 Oct 2024
    Share Share
    Atea Pharmaceuticals Updates Global Phase 3 SUNRISE-3 Trial Of Bemnifosbuvir
    Atea Pharmaceuticals Updates Global Phase 3 SUNRISE-3 Trial Of Bemnifosbuvir

    13 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/13/2945844/0/en/Atea-Pharmaceuticals-Provides-Update-on-Global-Phase-3-SUNRISE-3-Trial-Evaluating-Bemnifosbuvir-for-Treatment-of-COVID-19.html

    GLOBENEWSWIRE
    13 Sep 2024
    Share Share
    Atea Pharmaceuticals Publishes Data On Bemnifosbuvir's Activation
    Atea Pharmaceuticals Publishes Data On Bemnifosbuvir's Activation

    28 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/28/2936871/0/en/Atea-Pharmaceuticals-Announces-Publication-of-Additional-Data-Further-Highlighting-Bemnifosbuvir-s-Metabolic-Activation-Pathway.html

    GLOBENEWSWIRE
    28 Aug 2024
    Share Share
    Atea: Positive Initial Phase 2 Bemnifosbuvir+Ruzasvir Data In HCV At EASL
    Atea: Positive Initial Phase 2 Bemnifosbuvir+Ruzasvir Data In HCV At EASL

    05 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/05/2893808/16259/en/Assembly-Biosciences-Presents-New-Data-Highlighting-Hepatitis-D-Virus-Entry-Inhibitor-ABI-6250-at-the-EASL-Congress-2024.html

    GLOBENEWSWIRE
    05 Jun 2024
    Share Share
    Atea Shows Bemnifosbuvir-Ruzasvir HCV Combo Potential At EASL
    Atea Shows Bemnifosbuvir-Ruzasvir HCV Combo Potential At EASL

    22 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/22/2886350/0/en/Atea-Pharmaceuticals-Presents-New-Data-Showcasing-Potential-Best-in-Class-Combination-Profile-of-Bemnifosbuvir-and-Ruzasvir-for-Treatment-of-Hepatitis-C-Virus-at-EASL-Congress-2024.html

    GLOBENEWSWIRE
    22 May 2024
    Share Share